<qa>  What is the BID?Patients receive veliparib orally PO twice daily BID on days 1-7 and bendamustine hydrochloride intravenously IV over 30-60 minutes on days 1-2. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. 